The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Open accessAbstract
BACKGROUND: High plasma levels of nonfasting triglycerides are associated with an increased risk of ischemic cardiovascular disease. Whether lifelong low levels of nonfasting triglycerides owing to mutations in the gene encoding apolipoprotein C3 (APOC3) are associated with a reduced risk of ischemic cardiovascular disease in the general population is unknown. METHODS: Using data from 75,725 participants in two general-population studies, we first tested whether low levels of nonfasting triglycerides were associated with reduced risks of ischemic vascular disease and ischemic heart disease. Second, we tested whether loss-of-function mutations in APOC3, which were associated with reduced levels of nonfasting triglycerides, were also associated with reduced risks of ischemic vascular disease and ischemic heart disease. During follow-up, ischemic vascular disease developed in 10,797 participants, and ischemic heart disease developed in 7557 of these 10,797 participants. RESULTS: Participants with nonfasting triglyceride levels of less than 1.00 mmol per liter (90 mg per deciliter) had a significantly lower incidence of cardiovascular disease than those with levels of 4.00 mmol per liter (350 mg per deciliter) or more (hazard ratio for ischemic vascular disease, 0.43; 95% confidence interval [CI], 0.35 to 0.54; hazard ratio for ischemic heart disease, 0.40; 95% CI, 0.31 to 0.52). Heterozygosity for loss-of-function mutations in APOC3, as compared with no APOC3 mutations, was associated with a mean reduction in nonfasting triglyceride levels of 44% (P<0.001). The cumulative incidences of ischemic vascular disease and ischemic heart disease were reduced in heterozygotes as compared with noncarriers of APOC3 mutations (P=0.009 and P=0.05, respectively), with corresponding risk reductions of 41% (hazard ratio, 0.59; 95% CI, 0.41 to 0.86; P=0.007) and 36% (hazard ratio, 0.64; 95% CI, 0.41 to 0.99; P=0.04). CONCLUSIONS: Loss-of-function mutations in APOC3 were associated with low levels of triglycerides and a reduced risk of ischemic cardiovascular disease. (Funded by the European Union and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss-of-function variants in APOC3 confer protection against coronary artery disease, independent of LDL cholesterol levels [60, 112]”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“rare loss-of-function mutations in the lipoprotein lipase (LPL) gene are associated with higher plasma triglyceride levels and a higher risk of cardiovascular disease”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“while rare, loss-of-function mutations in the APOC3, ANGPTL3, and ANGPTL4 genes, which encode for natural inhibitors of LPL, are associated with lower triglyceride levels and a corresponding lower risk of cardiovascular disease.[9][10][11][12][13]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrary, loss-of-function mutations of the ApoC-III are associated with a lower risk of CVD [170–172].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [171]
The cited source says what the claim attributes to it.
In the citing paper
“Apolipoprotein C-III is a central regulator of triglyceride metabolism that limits the clearance of triglyceride-rich lipoproteins through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoprotein remnants. 6-8”
From Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Low-density lipoprotein (LDL) cholesterol and triglyceride-rich remnant lipoproteins are causally associated with risk of atherosclerotic vascular disease [3][4][5][6]”
From APOE and vascular disease: Sequencing and genotyping in general population cohorts (2023) · cites this paper as [4]
In the citing paper
“Mendelian randomization studies focused on variants in the genes encoding apoAV, apoCIII, lipoprotein lipase (LpL) and the angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, ANGPTL4, and ANGPTL8) have been highly informative.29–35”
In the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“Some rare heterozygous loss-of-function (LOF) variants are associated with reduced TG levels. These patients show protection from ASCVD providing important evidence for a causal role of TG for ASCVD.”
From Clinical review on triglycerides (2020) · cites this paper as [10]
In the citing paper
“Such LOF variants of APOC3 are also associated with reduced ASCVD risk.10”
From Clinical review on triglycerides (2020) · cites this paper as [10]
In the citing paper
“and is a genetically validated target to reduce ASCVD risk.8–10,64–66”
From Clinical review on triglycerides (2020) · cites this paper as [10]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD. 106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“Recent data from genetic studies utilizing a Mendelian randomization design have consistently linked both non-fasting TG levels as well as remnant cholesterol to increased risk of CVD events and all-cause mortality.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD.106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“Recent data from genetic studies utilizing a Mendelian randomization design have consistently linked both non-fasting TG levels as well as remnant cholesterol to increased risk of CVD events and all-cause mortality.86,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“defects in genes controlling TG metabolism, including APOC3, ANGPTL3 and ANGPTL4 that have been linked to reduced TG and are associated with reduced coronary calcification25 or reduced CVD risk.26-30”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Self-citationEffects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Pre-mRNA splicing and human diseasePreprint
Faustino, N. A., & Cooper, T. A. (2003) · Genes & Development · doi:10.1101/gad.1048803 · Cited by 1,248
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Self-citationRemnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Self-citation
Flagged first, then by citations
1 of the 39 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- 10.1016/S0140-6736(12)60312-2 · DOI · Paper page
Cited by
Sorted by citations
Items 401–500 of 923
Kypreos, K. E., Bitzur, R., Karavia, E. A., Xepapadaki, E., Panayiotakopoulos, G. D., & Constantinou, C. (2018) · Angiology · doi:10.1177/0003319718779533 · Cited by 26
D’Erasmo, L., Gallo, A., Costanzo, A. D., Bruckert, É., & Arca, M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1787380 · Cited by 24
Ge, F., Li, C., Iqbal, S., Arif, M., Li, F., Thafar, M. A., Yan, Z., Worachartcheewan, A., Xu, X., Song, J., et al. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac535 · Cited by 25
Butler, A. A., Price, C. A., Graham, J. L., Stanhope, K. L., King, S. M., Hung, Y.-H., Sethupathy, P., Wong, S. C., Hamilton, J., Krauss, R. M., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m089508 · Cited by 25
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname, M. H., Rocha, V. Z., & Santos, R. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00936-1 · Cited by 25
Merging Electronic Health Record Data and Genomics for Cardiovascular Research
Hall, J. L., Ryan, J. J., Bray, B. E., Brown, C. M., Lanfear, D. E., Newby, L. K., Relling, M. V., RISCH, N. J., Roden, D. M., Shaw, S. Y., et al. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/hcg.0000000000000029 · Cited by 24
Apolipoprotein C3 induces inflammasome activation only in its delipidated form
Hsu, C.-C., Shao, B., Kanter, J. E., He, Y., Vaisar, T., Witztum, J. L., Snell‐Bergeon, J. K., McInnes, G., Bruse, S., Gottesman, O., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01423-2 · Cited by 25
New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
Kim, J. Y., & Kim, N. H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.23 · Cited by 23
Aroner, S. A., Koch, M., Mukamal, K. J., Furtado, J. D., Stein, J. H., Tattersall, M. C., McClelland, R. L., & Jensen, M. K. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007824 · Cited by 23
Dai, W., Zhang, Z., & Zhao, S. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0923-1 · Cited by 23
Variants inANGPTL4and the Risk of Coronary Artery Disease
Morrison, A. R., Fu, Y., & O’Donnell, C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1607380 · Cited by 24
Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of LDL-C
Davidson, M. H. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx741 · Cited by 24
APOE and vascular disease: Sequencing and genotyping in general population cohorts
Rasmussen, K. L., Luo, J., Nordestgaard, B. G., Tybjærg-Hansen, A., & Frikke-Schmidt, R. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117218 · Cited by 22
Self-citationBallantyne, C. M., & Norata, G. D. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf606 · Cited by 23
Cardiovascular ageing: hallmarks, signaling pathways, diseases and therapeutic targets
Zheng, P., Yan, W., Ding, Y.-N., Zhang, Y., Chen, Z., Qian, J., & Ge, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02630-7 · Cited by 26
Wilken, M. R., Lambert, M. N. T., Christensen, C. B., & Jeppesen, P. B. (2022) · The Review of Diabetic Studies · doi:10.1900/rds.2022.18.42 · Cited by 22
Ramms, B., Patel, S., Sun, X., Pessentheiner, A. R., Ducasa, G. M., Mullick, A. E., Lee, R. G., Crooke, R. M., Tsimikas, S., Witztum, J. L., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158414 · Cited by 22
Recent developments in genome and exome-wide analyses of plasma lipids
Lange, L. A., Willer, C. J., & Rich, S. S. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000159 · Cited by 24
Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype
Sanin, V., Pfetsch, V., & Köenig, W. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0869-3 · Cited by 24
Blanco‐Vaca, F., Martín-Campos, J. M., Beteta-Vicente, Á., Canyelles, M., Martínez, S., Roig, R., Farré, N., Julve, J., & Tondo, M. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.01.036 · Cited by 22
Recent advances in novel therapies for lipid disorders
Tirronen, A., Hokkanen, K., Vuorio, T., & Ylä‐Herttuala, S. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz132 · Cited by 22
Genetic and Metabolic Determinants of Plasma Levels of ANGPTL8
Oldoni, F., Bass, K., Kozlitina, J., Hudson, H., Shihanian, L. M., Gusarova, V., Cohen, J. C., & Hobbs, H. H. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab120 · Cited by 20
Nordestgaard, A. T., & Nordestgaard, B. G. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf337 · Cited by 22
Self-citationManagement of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease
Brinton, E. A. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.09.012 · Cited by 22
Updates in Small Interfering RNA for the Treatment of Dyslipidemias
Carugo, S., Sirtori, C. R., Gelpi, G., Corsini, A., Tokgözoğlu, L. S., & Ruscica, M. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01156-5 · Cited by 22
Uncomplicating the Macrovascular Complications of Diabetes: The 2014 Edwin Bierman Award Lecture
Bornfeldt, K. (2015) · Diabetes · doi:10.2337/db14-1963 · Cited by 21
Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease
Brinton, E. A. (2015) · Cardiology Clinics · doi:10.1016/j.ccl.2015.02.007 · Cited by 22
Trenchevska, O., Nelson, R. W., & Nedelkov, D. (2016) · Bioanalysis · doi:10.4155/bio-2016-0060 · Cited by 21
Triglycerides and cardiovascular risk: Apolipoprotein B holds the key
Stock, J. K. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.03.004 · Cited by 21
Rodríguez-Mortera, R., Caccavello, R. J., Garay‐Sevilla, M. E., & Gugliucci, A. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.05.014 · Cited by 21
Jia, X., Rifai, M. A., Hussain, A., Martin, S. S., Agarwala, A., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00895-z · Cited by 22
Dowaidar, M. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/rvm3z · Cited by 25
Expanding the triglyceride range in clinical trials: therapeutic opportunities
Nordestgaard, A. T., Pradhan, A. D., Everett, B. M., MacFadyen, J. G., Bhatt, D. L., Visseren, F. L. J., Libby, P., Santos, R. D., Nissen, S. E., Nordestgaard, B. G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf074 · Cited by 20
Self-citationHassan, A., Tajuddin, N. N., & Shaikh, A. (2014) · Cardiology and Therapy · doi:10.1007/s40119-014-0032-9 · Cited by 20
Apolipoprotein C3 gene variants and the risk of coronary heart disease: A meta-analysis
Li, Y., Li, C., & Gao, J. (2016) · Meta Gene · doi:10.1016/j.mgene.2016.04.004 · Cited by 19
APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice
Cheng, X., Yamauchi, J., Lee, S., Zhang, T., Gong, Z., Muzumdar, R. H., Qu, S., & Dong, H. H. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.765917 · Cited by 21
Tajima, T., Morita, H., Ito, K., Yamazaki, T., Kubo, M., Komuro, I., & Momozawa, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-26453-x · Cited by 19
Rasmussen, I. J., Rasmussen, K. L., Thomassen, J. Q., Nordestgaard, B. G., Schnohr, P., Tybjærg‐Hansen, A., & Frikke‐Schmidt, R. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.08.004 · Cited by 23
Self-citationBenítez-Santana, T., Hugo, S. E., & Schlegel, A. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00280 · Cited by 19
HDL-cholesterol, genetics, and coronary artery disease: the myth of the ‘good cholesterol’?
Landmesser, U., & Hazen, S. L. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy299 · Cited by 20
Langlois, M. R., & Nordestgaard, B. G. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1036-1 · Cited by 19
Self-citationPan, B.-Y., Chen, C.-S., Chen, F.-Y., & Shen, M.-Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312759 · Cited by 19
Ballantyne, C. M., Gaudet, D., Rosenson, R. S., Hegele, R. A., Zhou, R., Melquist, S., Hellawell, J. L., & Leeper, N. J. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.496 · Cited by 20
Abramowitz, Y., Roth, A., Keren, G., Isakov, O., Shomron, N., Laitman, Y., Weissglas‐Volkov, D., Arbel, Y., Banai, S., Finkelstein, A., et al. (2016) · Coronary Artery Disease · doi:10.1097/mca.0000000000000357 · Cited by 20
Chhabra, M., Vidyasagar, K., Gudi, S. K., Sharma, J., Sharma, R., & Rashid, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269531 · Cited by 19
Rani, A., & Marsche, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051504 · Cited by 20
Mooser, V., & Currat, C. (2014) · Swiss Medical Weekly · doi:10.4414/smw.2014.14033 · Cited by 21
Impaired postprandial lipemic response in chronic kidney disease
Saland, J. M., Satlin, L. M., Zalsos-Johnson, J., Cremers, S., & Ginsberg, H. N. (2016) · Kidney International · doi:10.1016/j.kint.2016.02.031 · Cited by 19
Apoprotein C-III: A review of its clinical implications
Jin, J., Guo, Y., & Li, J. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.06.016 · Cited by 21
Wiesner, P., & Watson, K. E. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.03.004 · Cited by 21
Lowering apolipoprotein CIII protects against high-fat diet–induced metabolic derangements
Valladolid‐Acebes, I., Åvall, K., Recio-López, P., Moruzzi, N., Bryzgalova, G., Björnholm, M., Krook, A., Fauste, E., Ericsson, M., Landfors, F., et al. (2021) · Science Advances · doi:10.1126/sciadv.abc2931 · Cited by 18
Soto, L. G. D. L. P., Gutierrez-Uribe, J. A., Sharma, A. K., & Ramírez‐Jiménez, A. K. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.035 · Cited by 19
Khan, S. U., Saeed, S., Alsuhaibani, A. M., Fatima, S., Rehman, K. U., Zaman, U., Ullah, M., Refat, M. S. E.-D., & Lu, K. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101821 · Cited by 19
Girelli, D., Piubelli, C., Martinelli, N., Corrocher, R., & Olivieri, O. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.03.019 · Cited by 18
Nedelkov, D. (2017) · Proteomes · doi:10.3390/proteomes5040027 · Cited by 16
Siew, W. S., Tang, Y.-Q., Kong, C. K., Goh, B. H., Zacchigna, S., Dua, K., Chellappan, D. K., Duangjai, A., Saokaew, S., Phisalprapa, P., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168422 · Cited by 21
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
Ward, N. C., Chan, D. C., & Watts, G. F. (2022) · BioDrugs · doi:10.1007/s40259-022-00520-2 · Cited by 18
Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?
Rhainds, D., Brodeur, M. R., & Tardif, J. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1114 · Cited by 19
Feingold, K. R. (2017) · Europe PMC (PubMed Central) · Cited by 18
Hussain, A., & Ballantyne, C. M. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-100119-013612 · Cited by 19
Mahmoud, A., Abdelsayed, K., Mohamed, A. A., Najah, Q., Abdulkader, A., Ali, K., Tabassum, S., Abouzid, M. R., Abdelazeem, B., & Mills, J. D. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-024-02389-2 · Cited by 17
Sigfrids, F. J., Stechemesser, L., Dahlström, E. H., Forsblom, C. M., Harjutsalo, V., Weitgasser, R., Taskinen, M., Groop, P., & the FinnDiane Study Group (2021) · Journal of Internal Medicine · doi:10.1111/joim.13412 · Cited by 17
Malinowski, D., Bochniak, O., Luterek-Puszyńska, K., Puszyński, M., & Pawlik, A. (2023) · Genes · doi:10.3390/genes14071425 · Cited by 22
Zahger, D., Schwartz, G. G., Du, W., Szarek, M. J., Bhatt, D. L., Bittner, V., Budaj, A., Díaz, R., Goodman, S. G., Jukema, J. W., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.035 · Cited by 18
Behzadifar, M., Mirzaei, M., Behzadifar, M., Keshavarzi, A., Behzadifar, M., & Saran, M. (2015) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.17(4)2015.20277 · Cited by 17
Pokharel, Y., Sun, W., Polfus, L. M., Folsom, A. R., HEISS, G. M., Sharrett, A. R., Boerwinkle, E., Ballantyne, C. M., & Hoogeveen, R. C. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.033 · Cited by 17
Koch, M., Furtado, J. D., Jiang, Z. G., Gray, B. E., Cai, T., Sacks, F. M., Tjønneland, A. M., Overvad, K., & Jensen, M. K. (2017) · Journal of Lipid Research · doi:10.1194/jlr.p073288 · Cited by 17
Trinder, M., & Brunham, L. R. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000737 · Cited by 17
Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle
Valladolid‐Acebes, I., Berggren, P., & Juntti‐Berggren, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020932 · Cited by 16
Milonas, D., & Τζιόμαλος, Κ. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1582028 · Cited by 17
Patel, A. P., & Natarajan, P. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz032 · Cited by 18
Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes
Tomlinson, B., Chan, P., & Lam, C. W. K. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1750949 · Cited by 20
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention
Quispe, R., Sweeney, T. E., Varma, B., Agarwala, A., & Michos, E. D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01052-4 · Cited by 18
Apo CIII Proteoforms, Plasma Lipids, and Cardiovascular Risk in MESA
Sinari, S. A., Koška, J., Hu, Y., Furtado, J. D., Jensen, M. K., Budoff, M. J., Nedelkov, D., McClelland, R. L., Billheimer, D. D., & Reaven, P. D. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319035 · Cited by 16
Human proteoforms as new targets for clinical mass spectrometry protein tests
Nedelkov, D. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1362337 · Cited by 16
Effects of n-3 fatty acid treatment on monocyte phenotypes in humans with hypertriglyceridemia
Perrard, X. D., Lian, Z., Bobotas, G., Dicklin, M. R., Maki, K. C., & Wu, H. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.08.011 · Cited by 16
Fornari, E., Morandi, A., Piona, C. A., Tommasi, M., Corradi, M., & Maffeis, C. (2020) · Nutrients · doi:10.3390/nu12010214 · Cited by 16
Shetty, S. K., Walzem, R. L., & Davies, B. S. J. (2020) · Journal of Lipid Research · doi:10.1194/jlr.d119000388 · Cited by 18
Hypertriglyceridemia is associated with platelet hyperactivation in metabolic syndrome patients
Wang, T., Xu, J., Fu, L., & Li, L. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13508 · Cited by 17
Katzmann, J. L., Werner, C. M., Stojaković, T., März, W., Scharnagl, H., & Laufs, U. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01293-9 · Cited by 16
Silbernagel, G., Scharnagl, H., Kleber, M. E., Hoffmann, M. M., Delgado, G., Stojaković, T., Gary, T., Zeng, L., Ritsch, A., Zewinger, S., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.08.017 · Cited by 16
Read, R. W., Schlauch, K. A., Lombardi, V. C., Cirulli, E. T., Washington, N. L., Lu, J. T., & Grzymski, J. J. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.639418 · Cited by 16
Genetics of coronary artery disease – A clinician's perspective
Manda, S. V., Reddy, S., Naik, A., & Naik, S. R. (2014) · Indian Heart Journal · doi:10.1016/j.ihj.2014.12.008 · Cited by 15
Joint Associations of APOC3 and LDL-C–Lowering Variants With the Risk of Coronary Heart Disease
Wang, W., Li, R. P., Song, Z., Huang, N., Huang, T., Hua, X., & Tang, Y.-D. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0195 · Cited by 16
Protein restriction reprograms the multi-organ proteomic landscape of mouse aging
Lu, T., Xie, Y., Wang, Y., Lin, X., Cai, X., Zhang, Y., Nie, Z., Su, C., Gou, W., Zhang, H., et al. (2025) · Cell · doi:10.1016/j.cell.2025.10.004 · Cited by 19
Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia
Hooper, A. J., Bell, D. A., & Burnett, J. R. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2408369 · Cited by 16
Mottelson, M., Helby, J., Nordestgaard, B. G., Ellervik, C., Mandrup-Poulsen, T. R., Petersen, J., Bojesen, S. E., & Glenthøj, A. B. (2024) · BMJ · doi:10.1136/bmj-2023-079147 · Cited by 15
Self-citationBergmark, B. A., Marston, N., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Kang, Y. M., Murphy, S. A., Zhang, S. M., Lu, M. T., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.02.022 · Cited by 15
Wedervang‐Resell, K., Friis, S., Lonning, V., Smelror, R. E., Johannessen, C. H., Agartz, I., Ulven, S. M., Holven, K. B., Andreassen, O. A., & Myhre, A. M. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.11.039 · Cited by 15
Shaik, A., & Rosenson, R. S. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07168-0 · Cited by 15
Depression contributing to dyslipidemic cardiovascular risk in the metabolic syndrome
Lemche, A. V., Чабан, О., & Lemche, E. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0601-y · Cited by 15
Maraninchi, M., Padilla, N., Béliard, S., Berthet, B., Nogueira, J. P., Dupont-Roussel, J., Mancini, J., Corroller, A. B., Dubois, N., Grangeot, R., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.02.012 · Cited by 16
Is hypertriglyceridemia atherogenic?
Huet, F., Roubille, C., & Roubille, F. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000622 · Cited by 15
Baum, S. J., & Scholz, K. P. (2019) · Clinical Cardiology · doi:10.1002/clc.23220 · Cited by 15
Human genetic insights into lipoproteins and risk of cardiometabolic disease
Stitziel, N. O. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000389 · Cited by 14
Targeting RNA to lower triglycerides: long strides from short molecules
Qamar, A., Libby, P., & Bhatt, D. L. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz321 · Cited by 14
Marston, N., Bergmark, B. A., Prohaska, T. A., Moura, F. A., Zimerman, A., Alexander, V. J., Kang, Y. M., Weinland, J., Ran, X., Murphy, S. A., et al. (2026) · Circulation · doi:10.1161/circulationaha.126.080012 · Cited by 18
Assessing the dyslipidemias: to fast or not to fast?
Farukhi, Z. M., & Mora, S. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000615 · Cited by 16
Lipoprotein Assessment in the twenty-first Century
Lucero, D., Wolska, A. T., Aligabi, Z., Turecamo, S. E., & Remaley, A. T. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.009 · Cited by 16
Recent Apolipoprotein CIII trials
Tramontano, D., Bini, S., D’Erasmo, L., & Arca, M. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000849 · Cited by 14
Metadata
- Authors
- Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A.
- Affiliations
- University of Copenhagen (DK)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-03
- Volume
- 371
- Issue
- 1
- Pages
- 32-41
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2052644460
- Semantic Scholar
- 55f5e169d6f4d9a568cca4bbafe0790022e8bc16
- Cited by
- 919
- References
- 39
- Citations by year
- 2026: 50 · 2025: 76 · 2024: 49 · 2023: 46 · 2022: 65 · 2021: 64 · 2020: 95 · 2019: 71 · 2018: 71 · 2017: 99 · 2016: 113 · 2015: 87 · 2014: 32
- FWCI
- 75.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Gentofte Hospital
- Rigshospitalet
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, ischemic vascular disease, ischemic heart disease, cardiovascular risk, heterozygosity, genetic variants, triglyceride lowering, general population, hypertriglyceridemia, genetic epidemiology, Mendelian randomization
- MeSH terms
- Adult, Aged, Female, Genotype, Humans, Ischemia, Cholesterol, LDL, Liver, Male, Middle Aged, Mutation, Risk Factors, Triglycerides, Incidence, Myocardial Ischemia, Sequence Analysis, DNA, Apolipoprotein C-III, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
